Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Organized by the Multiple Myeloma Research Foundation (MMRF) & Sylvester Comprehensive Cancer Center, the meeting brought together leading experts in multiple myeloma who discussed the use of measurable residual disease (MRD) in clinical and trial settings, furthering our understanding of recent advances in the disease, and encouraged interactive discussion. VJHemOnc was official media partner of the meeting.
Miami Myeloma MRD 2021
13 October 2021 | Virtual Meeting
Organized by the Multiple Myeloma Research Foundation (MMRF) & Sylvester Comprehensive Cancer Center, the meeting brought together leading experts in multiple myeloma who discussed the use of measurable residual disease (MRD) in clinical and trial settings, furthering our understanding of recent advances in the disease, and encouraged interactive discussion. VJHemOnc was official media partner of the meeting.
Biology of MRD
Biology of MRD
Francesco Maura Sylvester Comprehensive Cancer Center, Miami, FL, United States
Next-Generation Sequencing
NGS-based MRD: applications in myeloma
Lanny Kirsch Adaptive Biotech, Seattle, WA, United States
Proteomics
Proteomics: MSKCC approach/Binding Site
Proteomics: Mayo Clinic approach
Angela Dispenzieri Mayo Clinic, Rochester, MN, United States
Liquid biopsies
Liquid biopsies: Dana-Farber Cancer Institute approach
Irene Ghobrial Dana-Farber Cancer Institute, Boston, MA, United States
Liquid biopsies: UHN approach
Liquid biopsies: Sylvester Cancer Center approach
Imaging
Imaging: Immuno-PET
Imaging: the tumor and the micro-environment
New MRD technologies – panel discussion
Panel discussion on new MRD technologies
Discussion with FDA
Fireside chat: FDA update of MRD for myeloma
Nicole Gormley Food and Drug Administration (FDA), Bethesda, MD, United States
Smoldering myeloma setting
Smoldering myeloma: PETHEMA trial
Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
Smoldering myeloma: NCI trial
Dickran Kazandjian Sylvester Comprehensive Cancer Center, Miami, FL, United States
Newly-diagnosed multiple myeloma setting
NDMM setting: Manhattan trial
NDMM setting: FORTE trial
Stefania Oliva University of Torino, Turin, Italy
NDMM setting: IFM2009 update
Aurore Perrot University of Toulouse, Toulouse, France
NDMM setting: New ADVANCE trial
Elisabet Manasanch The University of Texas MD Anderson Cancer Center, Afghanistan
NDMM setting: MagnetisMM-1 trial
Maintenance setting
Maintenance setting: MSKCC long-term lenalidomide maintenance
Current & future role of MRD in clinical trials – panel discussion
Panel Discussion: current and future role of MRD in clinical trials?
MRD in daily practice: today and tomorrow
MRD in daily practice: UChicago perspective
Benjamin Derman University of Chicago Medical Center, Chicago, IL, United States
MRD in daily practice: UCSF experience
Nina Shah University of California, San Francisco, CA, United States
MRD in daily practice: Mayo Clinic experience
Rafael Fonseca Mayo Clinic, Phoenix, AZ, United States
This meeting was supported by the following sponsors:
Explore our dedicated Multiple Myeloma Channel and MRD Focus for the latest updates
